GFAP and Alzheimer disease: Higher levels of GFAP were associated with cognitive and functional decline and with AD pathology and remained significant after controlling for age and sex (β = 0.24, 95% CI 0.04–0.43, p = .019; OR 3.3, 95% CI 1.9–5.6, p < .001).